Boston Therapeutics BTI320 Phase 2 study achieves full enrollment
Boston Therapeutics announced full enrollment of the BTI320 Phase 2 double-blind, placebo-controlled, multicenter trial. With the recent inclusion of Miami Dade Medical Research Institute in June and IOWA Diabetes in Feb, recruitment of patients reached full enrollment on August 1. The study will be used to confirm the efficacy parameters as well as to contribute to safety of the investigational material. The attenuation of post-prandial immediate rise in blood glucose in T2DM patients currently on metformin and/or sulfonylureas, a key determinant in blood sugar management in everyone both diabetic and non-diabetic, as measured by the Continuous Glucose Monitor Abbott Freestyle Libre Pro, the patented, investigational compound demonstrated in previous studies the effect on postprandial glucose reduction.